What is the elephant in the room when considering new therapies for fungal diseases?

Chaves, Alison Felipe Alencar; Xander, Patricia; Romera, Lavínia Maria Dal'Mas; Fonseca, Fernando Luiz Affonso; Batista, Wagner Luiz

Chaves, Alison Felipe Alencar; Xander, Patricia; Romera, Lavínia Maria Dal'Mas; Fonseca, Fernando Luiz Affonso; Batista, Wagner Luiz.

Afiliación

Chaves AFA; Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo, São Paulo, Brazil.
Xander P; Department of Pharmaceutical Sciences, Federal University of São Paulo, São Paulo, Brazil.
Romera LMD; Department of Microbiology, University of São Paulo, São Paulo, Brazil.
Fonseca FLA; Department of Pharmaceutical Sciences, Federal University of São Paulo, São Paulo, Brazil.
Batista WL; Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo, São Paulo, Brazil.

Crit Rev Microbiol ; 47(3): 275-289, 2021 May.

Article en En | MEDLINE | ID: mdl-33513315

Asunto(s)

Antifúngicos/uso terapéutico; Hongos/efectos de los fármacos; Micosis/veterinaria; Animales; Farmacorresistencia Fúngica; Hongos/genética; Hongos/fisiología; Humanos; Micosis/microbiología

Palabras clave

Antimicrobial resistance; antifungal drugs; fungal susceptibility; neglected diseases

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hongos / Micosis / Antifúngicos Límite: Animals / Humans Idioma: En Revista: Crit Rev Microbiol Asunto de la revista: MICROBIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google